Noninferior improvement in function over 24 weeks with Structovial HA vs Hylan G-F 20 HA for knee OA .
Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial.
Clin Exp Rheumatol. 2011 May-Jun;29(3):527-35279 patients with Kellgren-Lawrence grade II-III knee osteoarthritis were randomized to three weekly intraarticular injections of either F60027 sodium hyaluronate (Structovial; Pierre Fabre) or Hylan G-F20 (Synvisc). The primary purpose of this study was to examine if F60027 was noninferior to Hylan G-F20 for functional improvement over 24-week follow-up. Mean improvement in Lequesne Index score from baseline to 24 weeks was deemed to be noninferior in the F60027 group compared to the Hylan G-F20 group. Pain scores also did not significantly differ between groups, while rates of OMERACT-OARSI responders and treatment-emergent adverse events were similar between groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
